Investigating the relationship between metabolic diseases and heart artery health
The Impact of Cardiometabolic Factors on Coronary Artery and Cardiovascular Diseases: a Prospective Cohort Study
This study is trying to see how metabolic diseases like diabetes and obesity affect the health of heart arteries in people who already have coronary artery disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Ruijin Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT05117424 on ClinicalTrials.gov |
What this trial studies
The CArdioMetabolism and Atherosclerotic PlaqUe progreSsion (CAMPUS) study is a prospective cohort study that aims to explore how cardiometabolic factors influence the progression of coronary artery disease. It enrolls patients who have established coronary artery disease along with metabolic disorders such as diabetes, obesity, and chronic kidney disease. By systematically collecting data from these patients, the study seeks to understand the interplay between these conditions and their impact on heart health.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-80 with established coronary artery disease and associated metabolic abnormalities.
Not a fit: Patients with severe liver failure, active malignancies, or life expectancy of less than one year may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for patients with coronary artery disease and metabolic disorders.
How similar studies have performed: Other studies have shown promising results in understanding the relationship between metabolic disorders and cardiovascular health, suggesting that this approach is both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Age 18-80 years
* Established coronary artery disease or metabolic disorders, including:
1. Type 2 diabetes diagnosed by one of the following criteria:
HbA1c \>/= 6.5% Fasting plasma glucose \>/= 7.0 mmol/l (confirmed) 2h plasma glucose value during OGTT \>/= 11.1 mmol/l Already receiving glucose-lowering agents
2. Prediabetes
3. Obesity
4. Chronic kidney disease
5. Hyperuricemia
6. Dyslipidemia
Exclusion Criteria:
* Severe liver failure (Child-Pugh grade B to C)
* Severe anemia (hemoglobin \< 60g/L)
* Familial hypercholesterolemia
* Active malignant tumor
* Active autoimmune diseases on corticosteroids
* Acute or chronic infection
* Life expectancy \< 1 year
Where this trial is running
Shanghai
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine — Shanghai, China (Recruiting)
Study contacts
- Principal investigator: Ruiyan Zhang, M.D., Ph.D. — Ruijin Hospital, Shanghai Jiaotong School of Medicine
- Study coordinator: Xiaoqun Wang, M.D., Ph.D.
- Email: xiaoqun_wang@hotmail.com
- Phone: +86 21 13651839760
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.